ANTX · Insider Trading
AN2 Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by ANTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Patricia A. Martin | Director | A | +389 | — |
| 2026-10-13 | Gilbert Lynn Marks | Director | A | +2,283 | — |
| 2026-10-13 | Kabeer Aziz | Director | A | +2,465 | — |
| 2026-09-16 | Cameron C. Trenor III | Chief Medical Officer | A | +116,667 | — |
| 2026-09-11 | Robin Shane Readnour | Director | Sell | −1,108 | −$6.67K |
| 2026-09-08 | Robin Shane Readnour | Director | Sell | −16,119 | −$97.32K |
| 2026-09-04 | Sarah Joanne Williams | Principal Accounting Officer | Sell | −272 | −$1.50K |
| 2026-09-02 | Margaret M FitzPatrick | Director | Buy | +2,098 | +$11.60K |
| 2026-08-19 | Robin Shane Readnour | Director | Sell | −35,402 | −$212.70K |
| 2026-08-14 | Joseph S Zakrzewski | Director | G | −405,880 | — |
| 2026-07-10 | Gilbert Lynn Marks | Director | A | +2,789 | — |
| 2026-07-10 | Joshua M Eizen | See Remarks | Sell | −5,945 | −$24.80K |
| 2026-07-10 | Patricia A. Martin | Director | A | +766 | — |
| 2026-07-10 | Kabeer Aziz | Director | A | +2,852 | — |
| 2026-06-02 | Sarah Joanne Williams | Principal Accounting Officer | Sell | −265 | −$1.17K |
| 2026-04-10 | Gilbert Lynn Marks | Director | A | +3,775 | — |
| 2026-04-10 | Kabeer Aziz | Director | A | +3,775 | — |
| 2026-04-10 | Patricia A. Martin | Director | A | +1,192 | — |
| 2026-03-23 | Robin Shane Readnour | Director | MIXED | — | — |
| 2026-03-23 | Stephanie Wong | Director | MIXED | — | — |
| 2026-03-23 | Melvin K Spigelman | Director | MIXED | — | — |
| 2026-03-23 | Lucy Day | Chief Financial Officer | MIXED | — | — |
| 2026-03-23 | Margaret M FitzPatrick | Director | MIXED | — | — |
| 2026-03-23 | Eric Easom | Chief Executive Officer | MIXED | — | — |
| 2026-03-23 | Sanjay Chanda | Chief Development Officer | MIXED | — | — |
| 2026-03-23 | Joseph S Zakrzewski | Director | MIXED | — | — |
| 2026-03-23 | Gilbert Lynn Marks | Director | MIXED | — | — |
| 2026-03-23 | Patricia A. Martin | Director | MIXED | — | — |
| 2026-03-23 | Kabeer Aziz | Director | MIXED | — | — |
| 2026-03-23 | Joshua M Eizen | See Remarks | MIXED | — | — |
| 2026-03-05 | Sarah Joanne Williams | Principal Accounting Officer | Sell | −327 | −$347 |
| 2026-02-23 | Gilbert Lynn Marks | Director | A | +20,400 deriv. | — |
| 2026-02-23 | Robin Shane Readnour | Director | A | +20,400 deriv. | — |
| 2026-02-23 | Melvin K Spigelman | Director | A | +20,400 deriv. | — |
| 2026-02-23 | Joseph S Zakrzewski | Director | A | +20,400 deriv. | — |
| 2026-02-23 | Margaret M FitzPatrick | Director | A | +20,400 deriv. | — |
| 2026-02-23 | Sarah Joanne Williams | Principal Accounting Officer | A | +48,375 | — |
| 2026-02-23 | Patricia A. Martin | Director | A | +20,400 deriv. | — |
| 2026-02-23 | Joshua M Eizen | See Remarks | A | +50,000 | — |
| 2026-02-23 | Stephanie Wong | Director | A | +20,400 deriv. | — |
| 2026-02-23 | Kabeer Aziz | Director | A | +20,400 deriv. | — |
| 2026-02-23 | Lucy Day | Chief Financial Officer | A | +38,000 | — |
| 2026-02-23 | Eric Easom | Chief Executive Officer | A | +112,250 | — |
| 2026-02-23 | Sanjay Chanda | Chief Development Officer | A | +38,000 | — |
| 2026-01-14 | Patricia A. Martin | Director | A | +3,650 | — |
| 2026-01-14 | Kabeer Aziz | Director | A | +11,560 | — |
| 2026-01-14 | Gilbert Lynn Marks | Director | A | +11,560 | — |
| 2026-01-07 | Joshua M Eizen | See Remarks | Sell | −24,854 | −$24.96K |
| 2026-01-07 | Lucy Day | Chief Financial Officer | Sell | −8,807 | −$8.88K |
| 2026-01-07 | Sanjay Chanda | Chief Development Officer | Sell | −9,251 | −$9.33K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Braden Michael Leonard | 10%+ Owner | 3,017,432 | $10.95M |
| Kabeer Aziz | Director | 2,057,529 | $7.47M |
| Eric Easom | Chief Executive Officer | 1,434,396 | $5.21M |
| Robin Shane Readnour | Director | 633,842 | $2.30M |
| Joshua M Eizen | See Remarks | 206,554 | $749.79K |
| Joseph S Zakrzewski | Director | 145,538 | $528.30K |
| Sanjay Chanda | Chief Development Officer | 118,823 | $431.33K |
| Lucy Day | Chief Financial Officer | 118,363 | $429.66K |
| Cameron C. Trenor III | Chief Medical Officer | 116,667 | $423.50K |
| Gilbert Lynn Marks | Director | 84,156 | $305.49K |
| Sarah Joanne Williams | Principal Accounting Officer | 66,311 | $240.71K |
| Stephen David Prior | Chief Strategy Officer | 61,944 | $224.86K |
| Patricia A. Martin | Director | 19,252 | $69.88K |
| Margaret M FitzPatrick | Director | 10,708 | $38.87K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.